Oncology Activities
Immune Checkpoint Inhibitor/Chemotherapy Combinations for Metastatic Triple-Negative Breast Cancer: Emerging Clinical Data and Managed Care Considerations
0290-0000-20-397-L01-P
This live activity will determine the biological rationale for available and emerging treatment strategies involving immune checkpoint inhibitor (ICI)/chemotherapy combinations for the treatment of metastatic triple-negative breast cancer (mTNBC)
1-28-2021
1.50
Immune Checkpoint Inhibitors: Resolving Dosing Confusion to Better Care for Patients With Cancer
0290-0000-20-386-H01-P
This activity will compare the process by which dosing is determined for immune checkpoint inhibitors (ICIs) to that of small molecules.
1.50
Advanced or Metastatic Cervical and Endometrial Cancers: The Pharmacist's Role in Caring for Patients on Targeted and Immunotherapies
0290-0000-20-398-H01-P
This activity will focus on novel therapies in advanced or metastatic cervical and endometrial cancers and will also offer strategies for pharmacists to assist in patient care.
1.50
Establishing Clinical Pathways for the Management of Advanced/Metastatic Renal Cell Carcinoma: A Focus on New and Emerging First-Line Treatment Strategies
0290-0000-20-384-H01-P
This activity will help managed care pharmacists better delineate current and emerging treatment strategies for advanced/metastatic ccRCC.
1.50